| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/25/2011 | US20110206655 Fviii-independent fix-mutant proteins for hemophilia a treatment |
| 08/25/2011 | US20110206654 Methods of Modulating Gastrointestinal Tract Flora Levels with Alkaline Phosphatase |
| 08/25/2011 | US20110206653 Tetrazole compounds for reducing uric acid |
| 08/25/2011 | US20110206652 Methods for treating atherosclerosis |
| 08/25/2011 | US20110206651 Factor viii polymer conjugates |
| 08/25/2011 | US20110206642 Preventing obesity-related metabolic syndrome with melagonesis |
| 08/25/2011 | US20110206638 Compositions and methods for reducing the mutation rate of viruses |
| 08/25/2011 | US20110206637 Antiviral agents |
| 08/25/2011 | US20110206636 Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus |
| 08/25/2011 | US20110206635 Uses of il-12 in hematopoiesis |
| 08/25/2011 | US20110206625 Compositions and methods for modulating skin pigmentation |
| 08/25/2011 | US20110206620 Therapeutic Compositions for the Treatment of Dry Eye Disease |
| 08/25/2011 | US20110206616 Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery |
| 08/25/2011 | US20110206612 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor |
| 08/25/2011 | US20110206610 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 08/25/2011 | CA2790848A1 Methods and compositions to treat hemorrhagic conditions of the brain |
| 08/25/2011 | CA2790625A1 Use of transforming growth factor - beta 1 (tgf-.beta.1) inhibitor peptides for the treatment of corneal fibrosis and/or haze |
| 08/25/2011 | CA2790500A1 Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases |
| 08/25/2011 | CA2790495A1 Long-acting insulin analogue preparations in soluble and crystalline forms |
| 08/25/2011 | CA2790403A1 Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
| 08/25/2011 | CA2790329A1 Fibronectin based scaffold domain proteins that bind il-23 |
| 08/25/2011 | CA2790134A1 Pd-1 modulation and uses thereof for modulating hiv replication |
| 08/25/2011 | CA2790046A1 Use of pten-long leader sequence for transmembrane delivery of molecules |
| 08/25/2011 | CA2789337A1 Hsa-related compositions and methods of use |
| 08/25/2011 | CA2784211A1 Neuregulin antagonists and use thereof in treating cancer |
| 08/24/2011 | EP2360474A2 Methods and means for treatment of osteoarthritis |
| 08/24/2011 | EP2360276A1 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 08/24/2011 | EP2360260A1 BASB006 polynucleotide(s) and polypeptides from Neisseria meningitis |
| 08/24/2011 | EP2360259A2 Promyostatin peptides and methods of using same |
| 08/24/2011 | EP2360254A1 Assays for screening anti-pd-1 antibodies and uses thereof |
| 08/24/2011 | EP2360253A1 RNA sequence-specific mediators of RNA interference |
| 08/24/2011 | EP2360248A1 Ply-GBS mutant lysins |
| 08/24/2011 | EP2360185A2 Administration of agents for the treatment of inflammation |
| 08/24/2011 | EP2360181A1 IL-21 variants |
| 08/24/2011 | EP2360180A2 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| 08/24/2011 | EP2360169A2 PSMA antibodies |
| 08/24/2011 | EP2360168A1 Flavivirus fusion inhibitors |
| 08/24/2011 | EP2360166A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| 08/24/2011 | EP2359864A2 Targeting Vector-Phospholipid Conjugates |
| 08/24/2011 | EP2359855A2 Methods of administering anti-TNFalpha antibodies |
| 08/24/2011 | EP2359854A1 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 08/24/2011 | EP2359853A1 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 08/24/2011 | EP2359847A1 Modulation of beta-amyloid levels by beta-secretase bace2 |
| 08/24/2011 | EP2359846A1 Food ingredients and food products treated with an oxidoreductase and methods for preparing such food ingredients and food products |
| 08/24/2011 | EP2359845A1 Inhalant comprising modified superoxide dismutase |
| 08/24/2011 | EP2359844A2 Medicaments and proteins based on TGF-beta monomers for the treatment of wounds |
| 08/24/2011 | EP2359843A1 Pharmaceutical composition for treating a metabolic syndrome |
| 08/24/2011 | EP2359842A1 Netrin-related compositions and uses |
| 08/24/2011 | EP2359841A2 Survivin-derived peptides and use thereof |
| 08/24/2011 | EP2359840A1 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 08/24/2011 | EP2359834A1 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| 08/24/2011 | EP2359809A1 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
| 08/24/2011 | EP2359134A1 Methods for identifying modulating compounds of lymphangiogenesis, means therefore, compounds and uses thereof |
| 08/24/2011 | EP2358901A1 Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatment |
| 08/24/2011 | EP2358874A1 Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| 08/24/2011 | EP2358751A1 Truncated cd20 protein, deltacd20 |
| 08/24/2011 | EP2358749A2 Fgf21 mutants and uses thereof |
| 08/24/2011 | EP2358748A2 Methods and compositions for specific modulation of mcl-1 |
| 08/24/2011 | EP2358744A1 Cecropin-magainin hybrid peptides |
| 08/24/2011 | EP2358740A1 Cyclic peptides and uses thereof |
| 08/24/2011 | EP2358739A1 Peptide conjugates for suppressing an immune response, methods of making and uses therefor |
| 08/24/2011 | EP2358738A2 Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| 08/24/2011 | EP2358735A1 Azepinone derivatives |
| 08/24/2011 | EP2358731A2 Methods related to modified glycans |
| 08/24/2011 | EP2358439A1 Methods for treating hepatitis c virus infection |
| 08/24/2011 | EP2358382A2 NOVEL USES OF VEGFxxxB |
| 08/24/2011 | EP2358381A1 Compositions for potentiating apoposis signals in tumour cells |
| 08/24/2011 | EP2358380A1 Synthetic mimetics of host defense and uses thereof |
| 08/24/2011 | EP2358354A2 Method of protecting cells |
| 08/24/2011 | EP2358352A2 Compositions and methods for promoting bone formation |
| 08/24/2011 | EP2244719B1 Wound healing peptides and methods of use thereof |
| 08/24/2011 | EP1963362B1 Metastin derivatives and use thereof |
| 08/24/2011 | EP1901775B1 Kinin antagonists for treating bladder dysfunction |
| 08/24/2011 | EP1878793B1 Novel protein and preventive/remedy for neurodegenerative disease such as polyglutamine disease using the same |
| 08/24/2011 | EP1684736B1 Dna damage repair inhibitors for treatment of cancer |
| 08/24/2011 | EP1594895B1 Growth factor complexes and modulation of cell migration and growth |
| 08/24/2011 | EP1587923B1 Improved constructs for expressing lysosomal polypeptides |
| 08/24/2011 | EP1572128B1 RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/24/2011 | EP1571155B1 Peptides and medicinal compositions containing the same |
| 08/24/2011 | EP1531843B1 Method for treating cervical cancer |
| 08/24/2011 | EP1499729B1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 08/24/2011 | EP1497320B1 New gene expressed in prostate cancer and methods of use |
| 08/24/2011 | EP1423404B1 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/24/2011 | EP1369426B1 Peptides, derivatives thereof, process for producing the same, strain producing the same, and antiviral agent comprising the same as active ingredient |
| 08/24/2011 | EP1259544B1 Heterologous polypeptide of the tnf family |
| 08/24/2011 | EP1025121B1 Peptides capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor |
| 08/24/2011 | EP1023067B2 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 08/24/2011 | EP0981618B2 Anti-apo-2 antibody |
| 08/24/2011 | EP0754059B2 Methods and compositions useful for inhibition of angiogenesis |
| 08/24/2011 | EP0692984B2 Systemic effects of nitric oxide inhalation |
| 08/24/2011 | CN1733298B Microcapsule type blood substitute based on hemoglobin and process for preparing the same |
| 08/24/2011 | CN102165064A The tuberculosis RV2386C protein, compositions and uses thereof |
| 08/24/2011 | CN102164950A Novel toxin-antitoxin system |
| 08/24/2011 | CN102164948A Nonimmunosuppressive cyclosporine analogue molecules |
| 08/24/2011 | CN102164947A Peptide compound and method for producing same |
| 08/24/2011 | CN102164614A Use of an Ang-(1-7) receptor agonist in acute lung injury |
| 08/24/2011 | CN102164611A Therapeutic use of a growth factor, METRNL |
| 08/24/2011 | CN102164610A Compositions for the treatment of pain and/or inflamation |
| 08/24/2011 | CN102164609A Process for making bivalirudin |
| 08/24/2011 | CN102164608A Process for the preparation of pramlintide |